A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease
Keywords: دو بار در روز; Olodaterol; Long-acting beta-2-agonist; COPD; AE; adverse event; AUC0-12; area under the curve from 0 to 12Â h; AUC0-24; area under the curve from 0 to 24Â h; AUC12-24; area under the curve from 12 to 24Â h; BID; twice daily; CI; confidence interval